Version: 26 October, 2021 Page 22 of 28
Table 1. Profile of participants 18-year-olds, by case and vaccine status (regardless of time since vaccination), British Columbia and Quebec, Canada
British Columbia Quebec
Overall [N=380532] (column %) Vaccinated [N=285102] (row %)
Overall [N=854915] (column %) Vaccinated [N=630631] (row %)
Cases Hosp Controls Cases Hosp Controls Cases Hosp Controls Cases Hosp Controls
Total
27439 (7) 1582 (6)
353093 (93) 8630 (31) 217 (14) 276472 (78) 17234 (2) 878 (5)
837681 (98) 5868 (34) 176 (20) 624763 (75)
Age group (years)
18-49 20085 (73) 588 (37) 217157 (62) 5509 (27) 30 (5) 159310 (73) 13070 (76) 348 (40) 478750 (57) 3606 (28) 31 (9) 319674 (67)
50-69 5792 (21) 598 (38) 87688 (25) 2329 (40) 75 (13) 73864 (84) 3267 (19) 311 (35) 232291 (28) 1622 (50) 40 (13) 188911 (81)
70-79 1116 (4) 233 (15) 29538 (8) 551 (49) 47 (20) 26680 (90) 610 (4) 122 (14) 80884 (10) 429 (70) 47 (39) 74956 (93)
80+ 446 (2) 163 (10) 18710 (5) 241 (54) 65 (40) 16618 (89) 287 (2) 97 (11) 45756 (6) 211 (74) 58 (60) 41222 (90)
Median (Interquartile range) 37 (28-51) 57 (41-70) 42 (31-60) 42 (31-57) 71 (60-82) 44 (32-62) 36 (27-49) 56 (42-70) 45 (33-62) 44 (33-58) 73 (60-82) 49 (35-66)
Sex
Female 13313 (49) 647 (41) 198686 (56) 4595 (35) 92 (14) 159390 (80) 8756 (51) 372 (42) 502864 (60) 3195 (36) 77 (21) 369338 (73)
Male 14126 (51) 935 (59) 154407 (44) 4035 (29) 125 (13) 117082 (76) 8478 (49) 506 (58) 334817 (40) 2673 (32) 99 (20) 255425 (76)
Epidemiological week
22-25 (May 30-June 26) 1493 (5) 119 (8) 29093 (8) 97 (6) 5 (4) 11068 (38) 1227 (7) 62 (7) 111687 (13) 76 (6) 6 (10) 46541 (42)
26-30 (June 27-July 31) 1611 (6) 84 (5) 49434 (14) 346 (21) 13 (15) 35026 (71) 1118 (7) 50 (6) 166516 (20) 234 (21) 6 (12) 112998 (68)
31-35 (August 1-Sept 4) 12588 (46) 642 (41) 131403 (37) 3527 (28) 75 (12) 106647 (81) 6551 (38) 312 (36) 250102 (29) 2037 (31) 58 (19) 197160 (79)
36-39 (Sept 5-Oct 2) 11747 (43) 737 (47) 143163 (41) 4660 (40) 124 (17) 123731 (86) 8338 (48) 454 (51) 309376 (37) 3521 (42) 106 (23) 268064 (87)
Vaccinated
Two any mRNA vaccines 7535 (27)
198 (13) 252803 (72)
7535 (87) 198 (91) 252803 (91) 5379 (31) 155 (18) 576827 (69) 5379 (92) 155 (88) 576827 (92)
Two BNT162b2 5593 (20) 136 (9) 184987 (52) 5593 (65) 136 (63)
184987 (67)
4323 (25) 123 (14) 436106 (52) 4323 (74) 123 (70) 436106 (70)
Two mRNA-1273 1408 (5) 44 (3) 46596 (13) 1408 (16) 44 (20)
46596 (17)
914 (5) 25 (3) 123986 (15) 914 (16) 25 (14) 123986 (20)
Two mixed mRNA 533 (2) 18 (1) 21208 (6) 533 (6) 18 (8)
21208 (8)
142 (1) 7 (1) 16735 (2) 142 (2) 7 (4) 16735 (3)
Two ChAdOx1 652 (2) 17 (1) 8635 (2) 652 (8) 17 (8) 8635 (3) 236 (1) 14 (2) 18826 (2) 236 (4) 14 (8) 18826 (3)
Two mixed ChAdOx1/mRNA 443 (2) 2 (<1) 15034 (4) 443 (5) 2 (<1) 15034 (5) 253 (2) 7 (1) 29110 (3) 253 (4) 7 (4) 29110 (5)
Interval between doses
21-34 days (3-4 weeks) NA NA NA 6261 (2) 277 (3) 5984 (2) NA NA NA 430 (7) 19 (11) 23300 (4)
35-48 days (5-6 weeks) NA NA NA 18522 (7) 782 (9) 17740 (6) NA NA NA 484 (8) 6 (3) 35880 (6)
49-62 days (7-8 weeks) NA NA NA 106284 (37) 3286 (38) 102998 (37) NA NA NA 1636 (28) 15 (9) 149696 (24)
63-83 days (9-11 weeks) NA NA NA 103641 (36) 2802 (32) 100839 (36) NA NA NA 1808 (31) 50 (28) 204352 (33)
84-111 days (12-15 weeks) NA NA NA 44228 (16) 1284 (15) 42944 (16) NA NA NA 973 (17) 52 (30 130874 (21)
112+ days (16+ weeks) NA NA NA 6166 (2) 199 (2) 5967 (2) NA NA NA 537 (9) 34 (19) 80661 (13)
Time since second dose
0-13 days (0-1 weeks) NA NA NA 986 (11) 20 (9) 24123 (9) NA NA NA 762 (13) 13 (7) 69880 (11)
14-27 days (2-3 weeks) NA NA NA 397 (5) 9 (4) 29811 (11) NA NA NA 335 (6) 16 (9) 78087 (12)
28-55 days (4-7 weeks) NA NA NA 1793 (21) 30 (14) 75307 (27) NA NA NA 1299 (22) 27 (15) 173375 (28)
56-83 days (8-11 weeks) NA NA NA 2685 (31) 62 (29) 82806 (30) NA NA NA 1923 (33) 46 (26) 170639 (27)
84-111 days (12-15 weeks) NA NA NA 1814 (21) 74 (34) 45276 (16) NA NA NA 1121 (19) 57 (32) 90232 (14)
112-139 days (16-19 weeks) NA NA NA 390 (5) 14 (6) 9124 (3) NA NA NA 311 (5) 13 (7) 28130 (5)
140-167 days (20-23 weeks) NA NA NA 89 (1) 3 (1) 2385 (1) NA NA NA 89 (2) 3 (2) 12454 (2)
168-195 days (24-27 weeks) NA NA NA 130 (2) 0 (0) 2618 (1) NA NA NA 19 (<1) 0 (0) 1397 (<1)
196+ days (28+ weeks) NA NA NA 346 (4) 5 (2) 5022 (2) NA NA NA 9 (<1) 1 (1) 569 (<1)
Median, Interquartile range NA NA NA 68 (43-90) 76 (51-95) 58 (34-82) NA NA NA 64 (38-85) 79 (47-96) 54 (29-79)
Range (days) NA NA NA 0-250 2-231 0-265 NA NA NA 0-240 1-210 0-256
NA = Not applicable
1
Unless otherwise specified, displayed is the percentage of cases, hospitalized cases or controls who received a second vaccine dose by on or before specimen collection, by row category, regardless of time since second dose.
2
Displayed is the percentage of cases who were hospitalized.
3
All percentages displayed below this row are column %
4
One case twice vaccinated with unspecified mRNA vaccines in British Columbia.
5
Twelve controls twice vaccinated with unspecified mRNA vaccines in British Columbia
All rights reserved. No reuse allowed without permission.
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprintthis version posted October 26, 2021. ; https://doi.org/10.1101/2021.10.26.21265397doi: medRxiv preprint